Serum methotrexate and human chorionic gonadotropin concentrations during five-day chemotherapy for low-risk metastatic gestational trophoblastic neoplasia.
A recent report of serum methotrexate (MTX) levels measured during treatment of gestational trophoblastic neoplasia (GTN) led us to determine MTX and human chorionic gonadotropin (beta-hCG) levels in a patient with low-risk metastatic GTN with a pulmonary metastasis. Peak MTX concentrations exceeded 10(-6) mol/l considered by many investigators to be within the therapeutic range against many human tumors. Serum beta-hCG levels did not decline during MTX administration; however, after 5 days of MTX a steep dose-response curve was observed which continued during 5 courses of chemotherapy.
Hilgers
R D
RD
Department of Obstetrics and Gynecology, University of New Mexico Medical Center, Albuquerque.
Standefer
J C
JC
Bowling
M C
MC
Greeley
P
P
D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000556:secondary; D008727:Methotrexate / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000097:blood* / Q000188:drug therapy; D012307:Risk Factors; D013997:Time Factors; D014328:Trophoblastic Neoplasms / Q000097:blood* / Q000517:prevention & control / Q000556:secondary; D014594:Uterine Neoplasms / Q000097:blood* / Q000517:prevention & control
D006063:Chorionic Gonadotropin; D008727:Methotrexate